Thursday, October 1, 2015
C.R. Bard, a Murray Hill, N.J.-based multinational developer, manufacturer and marketer of medical technologies, has entered into a definitive agreement to acquire Kobayashi Pharmaceutical’s 50% ownership share in Medicon—the Osaka, Japan-based venture that the two companies have operated together since 1972—through a share redemption. The transaction is expected to close in early November, after which Medicon will be a wholly owned subsidiary of the company. The transaction has been approved by each company’s board of directors and is subject to customary closing conditions.